Sorin wants 10% share of Europe's DES (drug-eluting stent) market by November
This article was originally published in Clinica
Italian group Sorin is aiming to capture at least 10% of the European market for drug-eluting stents in the first 12 months of sales of its Janus tacrolimus-eluting device. So said CEO Drago Cerchiari in an interview with Clinica. The product was CE-marked in October 2004, and generated sales of E1m ($1.3m) in the first month.